Standout Papers

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-control... 2023 2026 202481
  1. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial (2023)
    Martina Schneider, Robert P. McMahon et al. The Lancet

Immediate Impact

21 standout
Sub-graph 1 of 10

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Prevalence of Chikungunya, Dengue, and West Nile arboviruses in Iran based on enzyme-linked immunosorbent assay (ELISA): A systematic review and meta-analysis
2025 Standout
2 intermediate papers

Works of Katrin Dubischar being referenced

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial
2020
Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers
2016

Author Peers

Author Last Decade Papers Cites
Katrin Dubischar 334 277 111 23 398
Konosuke Fukai 319 341 82 15 433
Nina Wressnigg 281 241 126 16 390
H.J. de Silva 231 251 46 15 395
Scott F. Paparello 178 173 116 13 371
Dora Estripeaut 202 115 131 30 337
Lívia Sacchetto 240 274 37 23 366
Vijay P. Bondre 308 298 66 12 414
Narayan Gyawali 243 303 55 42 400
Jyh-Hsiung Huang 328 358 42 10 431
L. Siger 218 181 77 16 339

All Works

Loading papers...

Rankless by CCL
2026